Clinical trials: Motor Fluctuations
Parkinson's Disease
Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in levodopa-treated PD patients with motor…
- Trial name
- NCT01556165
- Testing
- rasagiline
- Where
- 15 sites in China
- Volunteers
- 130 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease
A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
This is a multicenter, randomized, double blind, placebo controlled parallel group clinical study. Following a screening period of up to 28 days, eligible subjects will be randomized to receive adjunct treatment to oral LD/DDI…
- Trial name
- NCT02782481
- Testing
- ND0612
- Where
- Israel
- Sponsor
- NeuroDerm Ltd.
Parkinson's Disease
Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations
This is a multicentre, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of Perampanel (E2007) as an adjunctive therapy in levodopa treated PD subjects with motor fluctuations.
- Trial name
- NCT00505622
- Testing
- Perampanel
- Where
- France
- Volunteers
- 328 people
- Sponsor
- Eisai Limited
Parkinson's Disease
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations
This trial will evaluate the effects of Lu AF28996 in adults with Parkinson's disease (PD) experiencing motor fluctuations despite optimized non-invasive symptomatic treatment.
- Trial name
- DARE2 (NCT07514858)
- Testing
- Lu AF28996
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- H. Lundbeck A/S
Parkinson Disease
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa…
- Trial name
- NCT07432958
- Testing
- AP-472
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Appello Pharmaceuticals, Inc.
Parkinson Disease
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are…
- Trial name
- NCT04542499
- Testing
- Tavapadon
- Where
- 146 sites in United States, Australia and 12 more
- Volunteers
- 507 people
- Sponsor
- AbbVie
Advanced Parkinson's Disease
Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease
To explore the safety, tolerability, pharmacokinetics and efficacy of ABT-SLV187 in advanced Parkinson's disease (PD) patients with severe motor complications.
- Trial name
- NCT01479127
- Testing
- ABT-SLV187, Oral Levodopa/Carbidopa, Infusion Pump: CADD-Legacy® 1400 Pump
- Volunteers
- 8 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson's Disease
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
- Trial name
- NCT00203034
- Testing
- rasagiline mesylate, 1.0 mg rasagiline mesylate
- Where
- 4 sites in United States
- Volunteers
- 472 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson Disease, Off Episodes
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to determine the efficacy, safety and…
- Trial name
- NCT02469090
- Testing
- APL-130277
- Where
- 33 sites in United States, Canada
- Volunteers
- 141 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Idiopathic Parkinson's Disease
Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact
The primary objective of this study is to collect health economic data depicting the initial levels and natural progression over time of resource usage, Parkinson's disease (PD)-related costs, and health related quality of life…
- Trial name
- DAPHNE (NCT00141518)
- Testing
- Levodopa-carbidopa intestinal gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, percutaneous endoscopic gastrostomy tube (PEG tube)
- Volunteers
- 77 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson Disease
A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea
The primary purpose of this study is to evaluate the change at the 18th week from baseline in daily "off" time measured by participant diary and Parkinson's Disease Questionnaire-39 (PDQ-39) in participants with Parkinson's…
- Trial name
- NCT05312632
- Testing
- Safinamide Mesilate
- Where
- 20 sites in South Korea
- Volunteers
- 201 people
- Sponsor
- Eisai Korea Inc.
Parkinson Disease
Opicapone Treatment Initiation Open-Label Study
This is an observational study to describe the treatment patterns and clinical outcomes observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients experiencing "off" episodes with…
- Trial name
- OPTI-ON (NCT04787965)
- Testing
- Opicapone
- Where
- 6 sites in United States
- Volunteers
- 239 people
- Sponsor
- Neurocrine Biosciences
Parkinson's Disease
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
The purpose of the study is to assess the pharmacokinetics, pharmacodynamics, and safety of XP21279 sustained release formulation [administered with Lodosyn® (carbidopa)] and Sinemet® tablets in subjects with Parkinson's disease…
- Trial name
- NCT00914602
- Testing
- Sinemet 25-100 Oral Tablet, XP21279, Carbidopa Pill
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- XenoPort, Inc.
Parkinson Disease
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor…
- Trial name
- ATLANTIS (NCT06055985)
- Testing
- UCB0022
- Where
- 61 sites in United States
- Volunteers
- 207 people
- Sponsor
- UCB Biopharma SRL
Parkinson's Disease
Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study of E2007 in levodopa treated Parkinson's disease patients with motor fluctuations.
- Trial name
- NCT00368108
- Testing
- 2 mg perampanel, 4 mg perampanel
- Where
- 114 sites in United States, Canada
- Volunteers
- 752 people
- Sponsor
- Eisai Inc.
Parkinson Disease
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations
The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.
- Trial name
- NCT03877510
- Testing
- IPX203
- Where
- 98 sites in United States, Czechia and 6 more
- Volunteers
- 419 people
- Sponsor
- Impax Laboratories, LLC
Parkinson Disease
A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets
This study will be an open-label, randomized, three-period cross-over pharmacokinetic evaluation of CVT-301 compared with the Reference Listed Drug (RLD), orally administered carbidopa/levodopa, in healthy volunteers.
- Trial name
- NCT02812394
- Testing
- CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Acorda Therapeutics
Parkinson Disease
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson's disease (PD) patients to evaluate the add-on efficacy of opicapone 50 mg or an extra dose of levodopa…
- Trial name
- ADOPTION (NCT04990284)
- Testing
- Opicapone, L-DOPA/DDCI
- Where
- 25 sites in Germany, Italy and 3 more
- Volunteers
- 106 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations
A 48-month open label multi-centered extension study to evaluate the long-term safety, tolerability and efficacy of E2007 in patients with Parkinson's Disease with "wearing off" motor fluctuations and "on" period Dyskinesias.
- Trial name
- NCT01634360
- Testing
- Perampanel
- Volunteers
- 185 people
- Sponsor
- Eisai Inc.
Parkinson's Disease
A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor Fluctuations
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2 study. A total of 276 eligible Parkinson's disease participants with motor fluctuations will be enrolled and assigned to one of three…
- Trial name
- NCT07585565
- Testing
- GM1
- Volunteers
- 276 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.